Get started
Author

Suzanne R.L. Young

Focal Adhesion Kinase Is Important for Fluid Shear Stress-Induced Mechanotransduction in Osteoblasts
2008 · Suzanne RL Young, Rita Gerard-O'Riley, et al. · Journal of Bone and Mineral Research · 144
PDF
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
2005 · Curtis Balch, Pearlly Yan, et al. · Molecular Cancer Therapeutics · 141
PDF
Reduced Genomic Cytosine Methylation and Defective Cellular Differentiation in Embryonic Stem Cells Lacking CpG Binding Protein
2005 · Diana L. Carlone, Jeong-Heon Lee, et al. · Molecular and Cellular Biology · 101
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
2022 · Panagiotis A. Konstantinopoulos, Jung-min Lee, et al. · Gynecologic Oncology · 67
PDF
Activation of NF-κB by fluid shear stress, but not TNF-α, requires focal adhesion kinase in osteoblasts
2010 · Suzanne R.L. Young, Rita Gerard-O'Riley, et al. · Bone · 42
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
2018 · Sara M. Tolaney, Peter Kabos, et al. · Journal of Clinical Oncology · 40
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
2021 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 37
Non-Overlapping Functions for Pyk2 and FAK in Osteoblasts during Fluid Shear Stress-Induced Mechanotransduction
2011 · Suzanne R. L. Young, Julia M. Hum, et al. · PLoS ONE · 30
PDF
Nmp4/CIZ inhibits mechanically induced β‐catenin signaling activity in osteoblasts
2010 · Zhouqi Yang, Joseph P. Bidwell, et al. · Journal of Cellular Physiology · 22
Antisense Targeting of CXXC Finger Protein 1 Inhibits Genomic Cytosine Methylation and Primitive Hematopoiesis in Zebrafish
2006 · Suzanne R.L. Young, Christen Mumaw, et al. · Journal of Biological Chemistry · 22
CXXC Finger Protein 1 Is Required for Normal Proliferation and Differentiation of The PLB-985 Myeloid Cell Line
2007 · Suzanne R.L. Young, David G. Skalnik · DNA and Cell Biology · 20
Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy
2022 · Komal Jhaveri, Nadia Harbeck, et al. · Cancer Research · 19
Blockade of TNFR1 signaling: A role of oscillatory fluid shear stress in osteoblasts
2010 · Haifang Wang, Suzanne R. Young, et al. · Journal of Cellular Physiology · 18
Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
2018 · HS Rugo, P Kabos, et al. · Cancer Research · 15
Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
2023 · Komal Jhaveri, Joyce O’Shaughnessy, et al. · Cancer Research · 13
Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer
2021 · Elgene Lim, Murali Beeram, et al. · Cancer Research · 9
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
2025 · Giuseppe Curigliano, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 8
PDF
Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer
2019 · S Hurvitz, M Martin, et al. · Cancer Research · 6
Focal adhesion kinase is important for fluid shear stress-induced mechanotransduction in osteoblasts
2013 · Suzanne RL Young, Rita Gerard-O'Riley, et al. · Journal of Bone and Mineral Research · 3
PDF
Abstract P3-10-08: Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer
2019 · S Hurvitz, M Martin, et al. · Cancer Research · 2
Mechanical Regulation of Wnt/β-catenin Signaling in Bone Cells
2010 · Julia M. Hum, Suzanne R.L. Young, et al. · IUScholarWorks (Indiana University) · 1
PDF
Cellular Mechanisms of Mechanotransduction in Bone
2010 · Suzanne R.L. Young, Fredrick M. Pavalko · Springer eBooks · 1
51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study
2024 · K. Giridhar, C.X. Ma, et al. · ESMO Open
PDF
EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
2023 · N. Harbeck, K. Jhaveri, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Supplemental Data from Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
2023 · Curtis Balch, Pearlly Yan, et al.
Works count: 32
Citation count: 761
H-index: 14
I10-index: 15
Year
Topic
Type